Evaluation of mesoporous silicon/polycaprolactone composites as ophthalmic implants

Kashanian, Soheila; Harding, Frances J.; Irani, Yazad; Klebe, Sonja; Marshall, Kirsty; Loni, A.; Canham, Leigh; Fan, Dong; Williams, Keryn A.; Voelcker, Nicolas H.; Coffer, Jeffery L.

doi:10.1016/j.actbio.2010.03.031

Cited by 69 publications

(38 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Examination by SEM demonstrated that the pSi particles were partially embedded in the PCL but remained exposed on the surface, to permit drug loading after preparation of the composite material. This conferred a significant advantage over similar materials in which pSi particles were completely embedded within the PCL fibres (Kashanian et al, 2010), as exposure of many drugs to solvents or high temperatures during fabrication of the biomaterial would inevitably lead to drug denaturation and loss of activity. We further demonstrated that soaking the pSi particles in chloroform prior to pressing caused localised etching of the PCL fibres, improving attachment of pSi microparticles, and that particle retention could further be improved by the deposition of a thin layer of PCL strands on top of the particles.…”

Section: Discussionmentioning

confidence: 99%

“…Nonwoven fabrics of PCL were prepared as described previously (Kashanian et al, 2010;Fan et al, 2011). Briefly, a 25% by weight solution of PCL (MW 65 kDa) in chloroform was placed in a 5 ml glass syringe fitted with a 21 gauge needle, with an applied potential of 20 kV and tip to grounded Al collector distance of approximately 20 cm.…”

Section: Fabrication Of Pressed Psi-pcl Compositesmentioning

confidence: 99%

“…Porous silicon (pSi) shows potential as a biocompatible scaffold for applications in orthopaedics (Li et al, 1998;Coffer et al, 2005;Whitehead et al, 2008;Anderson et al, 2010), oncology (Zhang et al, 2005;Mann et al, 2011;Park et al, 2011) and ophthalmology (Low et al, 2006;Cheng et al, 2008;Low et al, 2009;Kashanian et al, 2010). For use in ophthalmic implants designed to deliver drugs or cells to the eye, the advantages of pSi include its large surface area for drug-loading and cell attachment, and good ocular biocompatibility (Low et al, 2009;Kashanian et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

“…For use in ophthalmic implants designed to deliver drugs or cells to the eye, the advantages of pSi include its large surface area for drug-loading and cell attachment, and good ocular biocompatibility (Low et al, 2009;Kashanian et al, 2010). However, pSi is somewhat inflexible, is opaque, and shards of the membrane form of the material exhibit sharp edges.…”

Section: Introductionmentioning

confidence: 99%

“…We have previously demonstrated that a composite material comprising a soft polymer such as polycaprolactone (PCL) encasing pSi particles mitigated some of these issues (Kashanian et al, 2010). Nevertheless, challenges with drug loading and release remained.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

A novel pressed porous silicon-polycaprolactone composite as a dual-purpose implant for the delivery of cells and drugs to the eye

Irani

Tian

Wang

et al. 2015

Experimental Eye Research

Self Cite

View full text Add to dashboard Cite

Abbreviations: BSS ophthalmic balanced salt solution; DMEM Dulbecco's Modified Eagle's Medium; EGF epidermal growth factor; FBS fetal bovine serum; FDA fluorescein diacetate; PBS phosphate buffered saline; PCL polycaprolactone; pSi nanostructured porous silicon; SEM scanning electron microscopy; TEM transmission electron microscopy. To investigate loading of large-molecule biologics, murine BALB/c 3T3 cells, responsive to epidermal growth factor, insulin and transferrin, were seeded on composite materials. The cells showed significantly more proliferation at 48 h when seeded on composites loaded with these biologics, than on unloaded composites. No cell proliferation was observed on PCL alone, indicating the biologics had loaded into the pSi microparticles. Drug release, measured by ELISA for insulin, indicated a burst followed by a slower, continuous release over six days. When implanted under the rat conjunctiva, the most promising composite material did not cause significant neovascularization but did elicit a macrophage and mild foreign body

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Fabrication Of Pressed Psi-pcl Compositesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A novel pressed porous silicon-polycaprolactone composite as a dual-purpose implant for the delivery of cells and drugs to the eye

Irani

Tian

Wang

et al. 2015

Experimental Eye Research

Self Cite

View full text Add to dashboard Cite

show abstract

Polycaprolactone based Nanobiomaterials

Singh

Maiti

2012

Biomedical Materials and Diagnostic Devices

View full text Add to dashboard Cite

Porous Silicon Nanoparticles Embedded in Poly(lactic‐co‐glycolic acid) Nanofiber Scaffolds Deliver Neurotrophic Payloads to Enhance Neuronal Growth

Zuidema

Dumont

Wang

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

Scaffolds made from biocompatible polymers provide physical cues to direct the extension of neurites and to encourage repair of damaged nerves. The inclusion of neurotrophic payloads in these scaffolds can substantially enhance regrowth and repair processes. However, many promising neurotrophic candidates are excluded from this approach due to incompatibilities with the polymer or with the polymer processing conditions. This work provides one solution to this problem by incorporating porous silicon nanoparticles (pSiNPs) that are pre-loaded with the therapeutic into a polymer scaffold during fabrication. The nanoparticle-drug-polymer hybrids are prepared in the form of oriented poly(lactic-co-glycolic acid) nanofiber scaffolds. We test three different therapeutic payloads: bpV(HOpic), a small molecule inhibitor of phosphatase and tensin homolog (PTEN); an RNA aptamer specific to tropomyosin-related kinase receptor type B (TrkB); and the protein nerve growth factor (NGF). Each therapeutic is loaded using a loading chemistry that is optimized to slow the rate of release of these water-soluble payloads. The drug-loaded pSiNP-nanofiber hybrids release approximately half of their TrkB aptamer, bpV(HOpic), or NGF payload in 2, 10, and >40 days, respectively. The nanofiber hybrids increase neurite extension relative to drug-free control nanofibers in a dorsal root ganglion explant assay.

show abstract

Evaluation of mesoporous silicon/polycaprolactone composites as ophthalmic implants

Cited by 69 publications

References 16 publications

A novel pressed porous silicon-polycaprolactone composite as a dual-purpose implant for the delivery of cells and drugs to the eye

A novel pressed porous silicon-polycaprolactone composite as a dual-purpose implant for the delivery of cells and drugs to the eye

Polycaprolactone based Nanobiomaterials

Porous Silicon Nanoparticles Embedded in Poly(lactic‐co‐glycolic acid) Nanofiber Scaffolds Deliver Neurotrophic Payloads to Enhance Neuronal Growth

Contact Info

Product

Resources

About